Browse > Article

Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease  

Koh, Won-Jung (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kwon, O Jung (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kang, Eun Hae (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Suh, Gee Young (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Chung, Man Pyo (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Hojoong (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Chung, Myung Jin (Division of Pulmonary and Critical Care Medicine, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Tae Sung (Division of Pulmonary and Critical Care Medicine, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Kyung Soo (Division of Pulmonary and Critical Care Medicine, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Nam Yong (Division of Pulmonary and Critical Care Medicine, Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Park, Young Kil (Korean Institute of Tuberculosis, Korean National Tuberculosis Association)
Bai, Gill Han (Korean Institute of Tuberculosis, Korean National Tuberculosis Association)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.3, 2004 , pp. 234-241 More about this Journal
Abstract
Background : There has been a gradual increase in the number of newly diagnosed cases of Mycobacterium avium complex (MAC) pulmonary disease. However, the optimal therapeutic regimen for the disease has not yet established and there is no report about the treatment outcome of MAC pulmonary disease in Korea. This study examined the effect of clarithromycin-based regimen in patients with pulmonary MAC disease without a HIV infection. Materials and Methods : Fifty-six patients with pulmonary MAC disease were diagnosed according to the American Thoracic Society criteria from January 2000 to December 2003 at this hospital. Of these patients, 15 were treated with clarithromycin, rifampin, and ethambutol for more than 6 months, together with streptomycin initially (first 6 months) in 8 patients. Results : Six months after the treatment, the sputum cultures converted from positive to negative in 8 patients (53%) and the radiological findings improved in 10 (67%). At 12 months 4 patients (44%) achieved sputum negative conversion and 6 patients out of 9 patients (67%) who were treated for more than 12 months showed radiological improvement. Overall, the sputum findings converted to negative in nine patients (60%) who underwent medical treatment. A pulmonary resection was successfully performed in one patient. Only one patient discontinued the treatment due to side effects such as gastrointestinal intolerance and optic neuritis. Conclusion : A combined regimen containing clarithromycin is relatively safe and tolerable even in the elderly outpatients. However, the results of this combined chemotherapy were unsatisfactory and new companion drugs for MAC pulmonary disease are needed. A resection may be considered for localized disease.
Keywords
Atypical mycobacteria; Mycobacterium avium complex; Lung diseases; Treatment; Korea;
Citations & Related Records

Times Cited By SCOPUS : 3
연도 인용수 순위
1 American Thoracic Sociery. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-25
2 British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Thorax 2000;55:210-8
3 Koh WJ, Kwon OJ, Kang EH, Jeon IS, Pyun YJ, Ham HS, et al. Clinical characteristics of the patients with Mycobacterium avium complex pulmonary disease. Tuberc Respir Dis 2003;54:33-44
4 Dutt AK, Stead WW. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med 1979;67:449-53
5 Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease:diagnostic and management limitations. Chest 1999;115:1033-40
6 Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 1995;107:1035-40
7 Lee H, Park HJ, Cho SN, Bai GH, Kim SJ. Species identification of mycobacteria by PCR-restriction fragment length polymorphism of the rpoB gene. J Clin Microbiol 2000;38:2966-71
8 Scientific Committee in Korean Academy of Tuberculosis and Respiratory Diseases. National survey of mycobacterial diseases other than tuberculosis in Korea. Tuberc Respir Dis 1995;42:277-94
9 Shiraishi Y, Nakajima Y, Takasuna K, Hanaoka T, Katsuragi N, Konno H. Surgery for Mycobacterium avium complex lung disease in the clarithromycinera. Eur J Cardiothorac Surg 2002;21:314-8
10 Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ, Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-92
11 American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95
12 Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996;153:1766-72
13 Hunter AM, Campbell IA, Jenkins PA, Smith AP. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellularecomplex. Thorax 1981;36:326-9
14 Koh WJ, Kwon OJ, Ham HS, Suh GY, Chung MP, Kim H, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens. Korean J Med 2003;65:10-21
15 Koh WJ, Kwon OJ, Kang EH, Suh GY, Chung MP, Kim H, et al. Successful pulmonary resection combined with chemotherapy for the treatment of Mycobacterium avium pulmonary disease: a case report. Tuberc Respir Dis. 2003;54:621-7
16 Nelson KG, Griffith DE, Brown BA, Wallace RJ, Jr. Results of operation in Mycobacterium avium-in-tracellulare lung disease. Ann Thorac Surg 1998;66:325-30
17 Koh WJ, Kwon OJ, Lee KS. Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients. Korean J Radiol 2002;3:145-57
18 Kobashi Y, Matsushima T. Comparison of clinical features in patients with pulmonary Mycobacteriumavium complex (MAC) disease treated before andafter proposal for guidelines. J Infect Chemother 2004;10:25-30
19 Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979;75:115-9
20 Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ, Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998;178:121-6
21 Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-72